These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24343051)

  • 1. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
    Arama V; Leblebicioglu H; Simon K; Zarski JP; Niederau C; Habersetzer F; Vermehren J; Bludzin W; Jinga M; Ulusoy S; Klauck I; Morais E; Bjork S; Lescrauwaet B; Kamar D; Zeuzem S;
    Antivir Ther; 2014; 19(3):245-57. PubMed ID: 24343051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
    Marcellin P; Arama V; Leblebicioglu H; Zarski JP; Zeuzem S; Mauss S; Sieklucki J; Acalovschi M; Usluer G; Klauck I; Morais E; Bjork S; Lescrauwaet B; Kamar D; Simon K;
    Antivir Ther; 2014; 19(3):235-43. PubMed ID: 23574686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-interventional study AI463-12 of real-world chronic HBV infection management--baseline characteristics and treatment patterns of Polish patients kohort.
    Simon K; Błudzin W; Dziambor A; Goryszewski D; Postawa-Kłosińska B; Sieklucki J; Kolasa K; Lescrauwaet B
    Przegl Epidemiol; 2013; 67(4):617-21, 709-12. PubMed ID: 24741906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
    Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
    Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
    Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
    Tornai I
    Orv Hetil; 2011 May; 152(22):869-74. PubMed ID: 21565754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries.
    Leblebicioglu H; Arama V; Causse X; Marcellin P; Ozaras R; Postawa-Klozinska B; Simon K; Suceveanu AI; Wiese M; Zeuzem S; Klauck I; Morais E; Bjork S; Lescrauwaet B; Kamar D; Zarski JP;
    J Viral Hepat; 2014; 21(9):662-70. PubMed ID: 24329883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
    Peters L; Mocroft A; Grint D; Moreno S; Calmy A; Jevtovic D; Sambatakou H; Lacombe K; De Wit S; Rockstroh J; Smidt J; Karpov I; Grzeszczuk A; Haziosmanovic V; Gottfredsson M; Radoi R; Kuzovatova E; Orkin C; Ridolfo AL; Zapirain J; Lundgren J
    Antivir Ther; 2018; 23(5):405-413. PubMed ID: 29303483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
    Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Protocol for the antiviral therapy of chronic hepatitis B].
    ;
    Orv Hetil; 2008 Dec; 149(49):2341-3. PubMed ID: 19042187
    [No Abstract]   [Full Text] [Related]  

  • 17. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
    Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
    Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
    J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.